Literature DB >> 25128600

Protective effect of stellate ganglion block on delayed cerebral vasospasm in an experimental rat model of subarachnoid hemorrhage.

Na Hu1, Yun Wu2, Bai-Zhao Chen3, Jin-Feng Han2, Mai-Tao Zhou4.   

Abstract

Stellate ganglion block (SGB) is a blockade of sympathetic ganglia innervating the head and neck, and is known to function through vasodilation of the target region. However, the effectiveness of SGB in relieving cerebral vasospasm (CVS) through dilation of intracerebral vessels has not been evaluated. The aim of the present study is to investigate the therapeutic effects of SGB in a rat model of subarachnoid hemorrhage (SAH) complicated by delayed CVS, and explore the underlying mechanisms. The SAH model was established by double injection of autologous arterial blood into the cisterna magna. We simulated SGB by transection of the cervical sympathetic trunk (TCST), and measured changes in the diameter, perimeter and cross-sectional area of the basilar artery (BA) and middle cerebral artery (MCA) to evaluate its vasodilatory effect. To investigate the underlying mechanisms, we determined the expression level of vasoactive molecules endothelin-1 (ET-1) and calcitonin gene-related peptide (CGRP) in the plasma, and apoptotic modulators Bcl-2 and Bax in the hippocampus. We found a significant increase in the diameter, perimeter and cross-sectional area of the BA and right MCA in SAH rats subjected to TCST. Application of SGB significantly reduced the expression of ET-1 while increasing that of CGRP in SAH rats. We also found a significant increase in the expression of Bcl-2 and decrease in the expression of Bax in the hippocampus of SAH rats subjected to TCST, when compared to untreated SAH rats. The mechanism of action of SGB is likely mediated through alterations in the ratio of ET-1 and CGRP, and Bax and Bcl-2. These results suggest that SGB can alleviate the severity of delayed CVS by inducing dilation of intracerebral blood vessels, and promoting anti-apoptotic signaling. Our findings provide evidence supporting the use of SGB as an effective and well-tolerated approach to the treatment of CVS in various clinical settings.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cerebral vasospasm; Experimental subarachnoid hemorrhage; Rat; Stellate ganglion block

Mesh:

Substances:

Year:  2014        PMID: 25128600     DOI: 10.1016/j.brainres.2014.08.012

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  5 in total

1.  Stellate ganglion block combined with intra-arterial treatment: a "one-stop shop" for cerebral vasospasm after aneurysmal subarachnoid hemorrhage-a pilot study.

Authors:  Marco Pileggi; Pascal J Mosimann; Maurizio Isalberti; Eike Immo Piechowiak; Paolo Merlani; Michael Reinert; Alessandro Cianfoni
Journal:  Neuroradiology       Date:  2021-03-16       Impact factor: 2.804

2.  Ultrasound guided double injection of blood into cisterna magna: a rabbit model for treatment of cerebral vasospasm.

Authors:  Yongchao Chen; Youzhi Zhu; Yu Zhang; Zixuan Zhang; Juan Lian; Fucheng Luo; Xuefei Deng; Kelvin K L Wong
Journal:  Biomed Eng Online       Date:  2016-02-06       Impact factor: 2.819

3.  Protective effects of atorvastatin on cerebral vessel autoregulation in an experimental rabbit model of subarachnoid hemorrhage.

Authors:  Jun-Hui Chen; Ting Wu; Li-Kun Yang; Lei Chen; Jie Zhu; Pei-Pei Li; Xu Hu; Yu-Hai Wang
Journal:  Mol Med Rep       Date:  2017-11-15       Impact factor: 2.952

4.  Effect of recombinant adeno-associated virus expressing calcitonin gene-related peptide on chick embryo umbilical artery vasospasm model.

Authors:  Yongjie Yuan; Si Yang; Chao Li; Kan Xu; Jinlu Yu
Journal:  Exp Ther Med       Date:  2017-11-01       Impact factor: 2.447

5.  Effects of stellate ganglion block on early brain injury in patients with subarachnoid hemorrhage: a randomised control trial.

Authors:  Jian Zhang; Ying Nie; Qiongni Pang; Xubiao Zhang; Qianting Wang; Jing Tang
Journal:  BMC Anesthesiol       Date:  2021-01-20       Impact factor: 2.217

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.